Prostate tumours - Histological classification and molecular aspects of prostate tumorigenesis

Endocrine Regulations

Volumn 41, Issue 1, 2007, Pages 45-57

  Liska, J ^a,b   Repiska, V ^a   Galbavy, ^a,c   Polak, S ^a   Varga, I ^a   Blasko, M ^d   Macejova, D ^b   Brtko, J ^b  

^a Physics and Informatics   (Slovakia)

^b INSTITUTE OF EXPERIMENTAL ENDOCRINOLOGY   (Slovakia)

^c St Elisabeth University College of Health and Social Work   (Slovakia)

^d Faculty of Medicine of Comenius University and University Hospital Bratislava   (Slovakia)

Author keywords

[No Author keywords available]

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

BLOOD; CELL TRANSFORMATION; CLASSIFICATION; HUMAN; MALE; PAGET NIPPLE DISEASE; PATHOLOGY; PROSTATE TUMOR; REVIEW;

CARCINOMA, DUCTAL; CELL TRANSFORMATION, NEOPLASTIC; HUMANS; MALE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS;

EID: 34547425316     PISSN: 12100668     EISSN: 13360329     Source Type: Journal    
DOI: None     Document Type: Article

References (59)

1. BOSTWICK DG, AMIN MB, DUNDORE P, MARSH W, SCHULTZ DS: Architectural patterns of high-grade prostatic intraepithelial neoplasia. Hum Pathol 24, 298-310, 1993
2. BURMESTER JK, SUAREZ BK, LIN JH, JIN CH, MILLE RD, ZHANG KQ, SALZMAN SA, REDING DJ, CATALONA, WJ: Analysis of candidate genes for prostate cancer. Hum Hered 57, 172-178, 2004
3. CHEVILLE JC, DUNDORE, PA, NASCIMENTO AG, MENESES M, KLEER E, FARROW GM, BOSTWIG DG: Leiomyosarcoma of the prostate. Report of 23 cases Report of 23 cases. Cancer 76, 1422-1427, 1995
4. CLEUTJENS KB, VAN EEKELEN CEM, VAN DER KORPUT HA, BRINKMANN AO, TRAPMAN J: Two androgen response regions cooperate in steroid hormone regulated activity of the prostate-specific antigen promoter, J Biol Chem 271, 6379-6388, 1996
5. DAVID A, MABJEESH N, AZAR I, BILTON S, ENGEL S, BERNSTEIN J, ROMANO J, et al.: Unusual alternative splicing within the human kallikrein genes KLK 2 and KLK 3 gives rise to novel prostate-specific proteins. J Biol Chem 277, 18084-18090, 2002
6. DEMARZO AM, NELSON WG, ISAACS WB, EPSTEIN JI: Patthological and molecular aspects of prostate cancer. Lancet 361, 955-964, 2003
7. DRAGO JR, MOSTOFI FK, LEE F: Introductory remarks and workshop summary. Urology 39, 2-8, 1992
8. DIEFENBACH MA, DORSEY J, UZZO RG, HANKS GE, GREENBERG RE, HORWITZ E, NEWTON F, ENGSTROM PF: Decision - making strategies for patients with localized prostate cancer. Semin Urol Oncol 20, 55-62, 2002
9. DUNDORE PA, CHEVILLE JC, NASCIMENTO AG, FARROW GM, BOSTWICK DG: Carcinosarcoma of the prostate. Report of 21 cases. Cancer 76, 1035-1042, 1995
10. EBLE JN, SAUTER G, EPSTEIN JI, SESTERHENN IA: Tumours of the prostate. In: Pathology and genetics of tumours of the urinary system and male genital organs. WHO classification of tumours (Eble JN, Sauter G, Epstein JI, Sesterhenn IA, eds), pp. 159-214. IARC Press Lyon 2004
11. EGEVAD L, GRANFORS T, KARLBERG L, BERGH A, STATTIN P: Prognostic value of the Gleason score in prostate cancer. In: Pathology and genetics of tumours of the urinary system and male genital organs. WHO classification of tumours (Eble JN, Sauter G, Epstein JI, Sesterhenn IA, eds.), pp. 167-214. IARC Press Lyon, 2004
12. EPSTEIN JL: How should atypical prostate needle biopsy be reported? Controversies regarding the term ASAP. Hum Pathol 30,1401-1402, 1999
13. EPSTEIN JI, CHO KR, QUINN BD: Relationship of severe dysplasia to stage A (incidental) adenocarcinoma of the prostate. Cancer 65, 2321-2327, 1990.
14. EPSTEIN JL: The evaluation of radical prostatectomy specimens. Therapeutic and prognostic implications. Pathol Annu 26, 159-210, 1991
15. EPSTEIN JI, GRIGNON DJ, HUMPHREY PA, MCNEAL JE, SESTERHENN IA, TRONCOSO P, WHEELER TM: Interobserver reproducibility in the diagnosis of prostatic intraepithelial neoplasia. Am J Surg Pathol 19, 873-886, 1995
16. EPSTEIN JL, YANG XJ: Prostatic duct adenocarcinoma. In: Prostate Biopsy Interpretation, pp.185-197. Lippincot Wiliams and Wilkins, Philadelphia 2002
17. ERBERSDOBLER A, GURSES N, HENKE RP: Numerical chromosomal changes in high-grade prostatic intraepithelial neoplasia (PIN) and concomitant invasive carcinoma. Pathol Res Pract 192, 418-427, 1996
18. GAUDIN PB, ROSAI J, EPSTEIN JL: Sarcomas and related proliferative lesions of specialized prostatic stroma: a clinicopathologic study of 22 cases. Am J Surg Pathol 22,148-162, 1998
19. GHOSSEIN RA, SCHER HI, GERALD WL, KELLY WK, CURLEY T, AMSTERDAM A, ZHANG ZF, ROSAI J: Detecting of circulating tumor cells in patients with localized and metastatic prostatic carcinoma: clinical implications. J Clin Oncol 13, 1195-1200, 1995
20. GLEASON DF: Histologic grading and clinical staging of prostatic carcinoma. In: Pathology and genetics of tumours of the urinary system and male genital organs. WHO classification of tumours (Eble JN, Sauter G, Epstein JI, Sesterhenn IA, eds.), pp.167-214. IARC Press, Lyon 2004
21. GOEBBELS R, AMBERGER L, WERNERT N, DHOM G: Urothelial carcinoma of the prostate. Appl Pathol 3, 242-254, 1985
22. GREEN GA, HANLON AL, AL SALEEM T, HANKS GE: A Gleason score of 7 predicts a worse outcome for prostate carcinoma patients treated with radiotherapy. Cancer 83, 971-976, 1998
23. GRIGNON DJ: Minimal diagnostic criteria for adenocarcinoma of the prostate. J Urol Pathol 8, 31-44, 1998
24. HEDRIK L, EPSTEIN JL: Use of keratin 903 as an adjunct in the diagnosis of prostate carcinoma. Am J Surg Pathol 13, 389-396, 1989
25. HERNANDEZ J, THOMPSON IM: Prostate-specific antigen: a review of the validation of the most commonly used cancer biomarker. Cancer 101, 894-904, 2004
26. HUMPHREY PA, KALEEM Z, SWANSON PE, VOLLMER RT: Pseudohyperplastic prostatic adenocarcinoma. Am J Surg Pathol 22, 1239-1246, 1998
27. IGNATOFF JM, OEFELEIN MG, HERZ B, WATKIN B, KAUL KL: Prostate specific antigen (PSA) reverse transcriptase-polymerase chain reaction (RT-PCR) assay in preoperative staging of prostate cancer. J Urol 2, 417-427, 1996
28. ITO K: Advancements in PSA-based screening for prostate cancer. Rinsho Byori. 52, 611-617, 2004
29. KAMBHAM N, TAYLOR JA TROXEL A, RUBIN MA: Atypical small acinar proliferation in prostate needle biopsy: a clinically significant diagnostic category. J Urol Pathol 10, 177- 188, 1999
30. LEAK B, WEI JT, GABEL M, PEABODY JO, MENON M, DEMERS R, TEWARI A: Relevant patient and tumor considerations for early prostate cancer treatment. Semin Urol Oncol 20, 39-44, 2002
31. LOBE TE, WIENWR E, ANDRASSY RJ, BAGWELL CE, HAYS D, CRIST WM, WEBBER B, BRENEMAN JC, REED MM, TEFFT MC, HEYN R: The argument for conservative delayed surgery in the management of prostatic rhabdomyosarcoma. J Pediatr Surg 31, 1084-1087, 1996
32. MONTIRONI R, MAZZUCCHELLI R, ALGABA F, LOPEZ-BELTRAN A: Morphological identification of the patterns of prostatic intraepithelial neoplasia and their importance. J Clin Pathol 53, 655-665, 2000
33. MONTIRONI R, MAZZUCCHELLI R, SCARPELLI M: Precancerous lesions and conditions of the prostate: from morphological and biological characterization to chemoprevention. Ann.NY Acad Sci 963, 169-184, 2002
34. MORENO JG, CROCE CM, FISEHER R, MONNE M, VIHKO P, MULHOLLAND SG, GOMELLA LG: Detection of hematogenous micrometastasis in patients with prostate cancer. Cancer Res 52, 6110-6112, 1992
35. MOSTOFI FK, SESTERHENN I, SOBIN LH: Histological typing of prostate tumours. International histological classification of tumours, No 22, pp. 17-23.WHO, Geneva 1980
36. MURPHY GP, BUSCH C, ABRAHAMSSON PA, EPSTEIN JI, MCNEAL JE, MILLER GJ, MOSTOFI FK, NAGLE RB, NORDLING S, PARKINSON C: Histopathology of localized prostate cancer. Consensus Conference on Diagnosis and Prognostic Parameters in Localized Prostate Cancer. Stockholm, Sweden, May 12-13. J Urol Nephrol Suppl 162, 7-42, 1993
37. NELSON RS, EPSTEIN JI: Prostatic carcinoma with abundant xanthomatous cytoplasm. Foamy gland carcinoma. Am J Surg Pathol 20, 419-426, 1996
38. NICOLAISEN GS, WILLIAMS RD: Primary transitional cell carcinoma of prostate. Urology 24, 544-549, 1984
39. NIXON RG, CHANG SS, LAFLEUR BJ, SMITH JA, COOKSON MS: Carcinoma in situ and tumor nultifocality predict the risk of prostatic urethral involvement at radical cystectomy in men with transitional cell carcinoma of the bladder. J Urol 167, 502-505, 2002
40. NOGUCHI M, MIYAJIMA J, ITOH K, NODA S: Detection of Circulating Tumor Cells in Patients With Prostate Cancer Using Prostate Specific Membrane-Derived Primers in the Polymerase Chain Reaction. Int J Urol 4, 374-379, 1997
41. OLIAI BR, KAHANE H, EPSTEIN JI: Can basal cells be seen in adenocarcinoma of the prostate?: an immunohistochemical study using high molecular weight cytokeratin (clone 34betaE12) antibody. Am J Surg Pathol 26, 1151-1160, 2002
42. ORDONEZ NG, RO JY, AYALA AG: Metastatic prostatic carcinoma presenting as an oncocytic tumor. Am J Surg Pathol 16, 1007-1012, 1992
43. OYAMA T, ALLSBROOK WC, KUROKAWA K, MATSUDA H, SEGAWA A, SANO T, SUZUKI K, EPSTEIN I: A comparison of interobserver reproducibility of Gleason grading of prostatic carcinoma in Japan and the United States. Arch Path Lab Med 129, 1004-1010, 2005
44. PIŃEIRO LM, RIOS E, GOMARIZ MM, PASTOR M, CABO M, PICAZO ML, PALACIOS J, PERONA R: Molecular Staging of Prostatic Cancer with RT-PCR Assay for Prostate-Specific Antigen in Peripheral Blood and Lymph Nodes: Comparison with Standard Histological Staging and Immunohistochemical Assessment of Occult Regional Lymph Node Metastases. European Urology 43, 342-350, 2003
45. PROPPE KH, SCULLY RE, ROSAI J: Postoperative spindle cell nodules of genitourinary tract resembling sarcomas. Am J Surg Pathol 106, 624-627, 1982
46. QIAN J, WOLLAN P, BOSTWICK DG: The extent and multicentricity of high-grade prostatic intraepithelial neoplasia in clinically localized prostatic adenocarcinoma. Hum Pathol 28, 143-148, 1997
47. RO JY, AMIN MB, SAIHIN AA, AYALA AG: Tumors and tumorous conditions of the male genital and urinary tract In: Diagnostic histopathology of tumors, Vol 1 (Fletcher CDM, ed), pp. 773-774. Churchill Livingstone, London 2001
48. RO JY, EL-NAGGAR A, AYALA AG, MODY DR, ORDONEZ NG: Signet-ring-cell carcinoma of the prostate. Electron-microscopic and immunohistochemical studies of eight cases. Am J Surg Pathol 12, 453-460, 1988
49. SAKAI I, HARADA KI, KURAHASHI T, YAMANAKA K, HARA I, MIYAKE H: Analysis of differences in clinicopathological features between prostate cancers located in the transition and peripheral zones. Int J Urol 13, 368-372, 2006
50. SCHMITTGEN TD, TESKE S, VESSELLA RL, TRUE LD, ZAKRAJSEK BA: Expression of prostate specific membrane antigen and three alternatively spliced variants of PSMA in prostate cancer patients. Int J Cancer 107, 323-329, 2003
51. SIGNORETTI S, WALTREGNY D, DILKS J, ISAAC B, LIN D, GARRAWAY L, YANG A, MONTIRONI R, MCKEON F, LODA M: p63 is a prostate basal cell marker and is required for prostate development. Am J Pathol 157, 1769-1775, 2000
52. STEPHAN C, JUNG K, DIAMANDIS EP, RITTENHOUSE HG, LEIN M, LOENING SA: Prostate-specific antigen, its molecular forms, and other kallikrein markers for detection of prostate cancer. Urology 59, 2-8, 2002
53. TAKASHI M, SAKATA T, NAGAI T, KATO T, SAHASHI M, KOSHIKAWA T, MIYAKE K: Primary transitional cell carcinoma of prostate: case with lymph node metastasis eradicated by neoadjuvant methotrexate, vinblastine, doxorubicin, and cisplatin (M-VAC) therapy. Urology 36, 96-98, 1990
54. TASCH J, GONG M, SADELAIN M, HESTON WD: A unique folate hydrolase, prostate-specific membrane antigen (PSMA): a target for immunotherapy? Crit Rev Immunol 21, 249-261, 2001
55. TRANN TT, SENGUPTA E, YANG XJ: Prostatic foamy gland carcinoma with aggressive behaviour: clinicopathol, imunohistochemical, and ultrastructural analysis. Am J Surg Pathol 25, 618-623, 2001
56. UCHIJIMA Y, ITO H, TAKAHASHI M, YAMASHIMA M: Prostate mucinous adenocarcinoma with signet ring cell. Urology 36, 267-268, 1990
57. XIAO Z, ADAM BL, CAZARES LH, CLEMENTS MA, DAVIS JW, SCHELLHAMMER PF, DALMASSO EA, WRIGHT GLJR: Quantitation of serum prostate-specific membrane antigen by a novel protein biochip immunoassay discriminates benign from malignant prostate disease. Cancer Res 15, 6029-6033, 2001
58. WALKER AN, MILLS SE, FECHNER RE, PERRY JM: Endometrial adenocarcinoma of the prostatic urethra arising in a villous polyp. A light microscopic and immunoperoxidase study. Arch Path Lab Med 106, 624-627, 1982
59. WOOD DOJR, MONTIE JE, PONTES JE, VANDERBRUG MEDENDROP S, LEVIN HS: Transitional cell carcinoma of the prostate in cystoprostatectomy specimens removed for bladder cancer. J Urol 141, 346-349, 1989